Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

Абдулганиева, Д. И.; Бакулев, А. Л.; Belousova, Elena; Веселов, А. В.; Коротаева, Т. В.; Лила, А. М.; Loginova, E.; Sokolovskiy, E. V.; Хобейш, М. М.; Шапина, М. В.; Щукина, О. Б.

doi:10.18786/2072-0505-2020-48-050

Alʹm. klin. med.

2020

DOI: 10.18786/2072-0505-2020-48-050

|View full text |Cite

Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

Д. И. Абдулганиева

А. Л. Бакулев

Elena Belousova

et al.

Abstract: Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important. The paper provides the expert consensus on the definition of the early stage of Ps, PsA, and IBDs, their treatment goals and main unfavorable prognostic factors. It also gives the rationale … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article5

Relationship

Self Cite2

Independent3

Authors

Journals

Cited by 9 publications

References 113 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Supportive local treatment of diseases of the distal colon of various inflammatory genesis in the outpatient department

Belik,

Kovalev,

Mirkin

et al. 2024

Ambulatornaya khirurgiya

View full text Add to dashboard Cite

Introduction. Currently, along with the improvement of the scheme of combined drug therapy with first-line anti-inflammatory drugs, important importance is attached to adjuvant topical methods of treating diseases of the distal colon of various inflammatory genesis.Aim. Evaluate the clinical efficacy of the drug on sodium hyaluronate as an adjuvant topical agent in the complex treatment of patients with diseases of the distal colon.Materials and methods. A comparative analysis of the results of drug treatment of 97 patients with diseases of the distal colon of various inflammatory genesis, which were divided into two groups, was carried out. In 46 (47.4%) patients of the I (control) group, standard drug therapy with basic anti-inflammatory drugs was performed; 51 (52.6%) patients – II (main) group, the standard program of drug treatment was supplemented with instillations into the rectum of the drug on sodium hyaluronate (0.8 mg of hyaluronic acid in 1 ml). The comparative assessment of the results of treatment took into account the severity of clinical, laboratory and endoscopic manifestations of the disease.Results. In patients of the main group, there was a significant reduction in the healing time of erosions and ulceration of the mucous membrane of the distal colon compared with patients in the control group (29.4 ± 5.7 days, respectively, versus 52.8 ± 6.2 days). Also, in patients of the main group, it was possible to achieve stable clinical and laboratory remission of the disease at an earlier time, restoration of patients’ ability to work, and improvement of their quality of life.Conclusion. The results obtained by us allow us to recommend the drug on sodium hyaluronate as an additional topical drug for the medical treatment of chronic diseases of the distal colon of various inflammatory genesis in outpatient settings.

show abstract

Supportive local treatment of diseases of the distal colon of various inflammatory genesis in the outpatient department

Belik,

Kovalev,

Mirkin

et al. 2024

Ambulatornaya khirurgiya

View full text Add to dashboard Cite

show abstract

Ankylosing spondylitis in combination with Crohn's disease: clinical case

Тарасова

Shilova

Koroleva

2021

Medicinskij alfavit

View full text Add to dashboard Cite

Introduction. Ankylosing spondylitis and Crohn's disease are chronic recurrent autoimmune diseases. In case of a combined course their activity tends to progress, regardless of the phase of the underlying disease.The aim of the study. To analyze the combination of ankylosing spondylitis and Crohn's disease, issues of its diagnosis and selection of therapy.Results. The combination of ankylosing spondylitis and Crohn's disease tend to progress independently, regardless of the phase of the underlying disease. The main problem that complicates diagnosis is the lack of a unifed approach to the defnition of extra skeletal and extraintestinal manifestations.Conclusion. The management of patients with a combination of ankylosing spondylitis and Crohn's disease is a common problem of rheumatologists and gastroenterologists. An interdisciplinary approach will allow timely diagnosis of extra-skeletal and extra-intestinal manifestations and correct therapy.

show abstract

Choice of frst drug of genetically engineered therapy: Benefts of guselcumab

Круглова

Шатохина

Polonskaya

et al. 2022

Medicinskij alfavit

View full text Add to dashboard Cite

When choosing the frst drug for genetically engineered biological therapy (GEBT), the following are taken into account: the psoriasis phenotype, diagnosed PsA or predictors of its development, the presence of comorbid pathology, contraindications, dosing regimen, the rate of onset of the effect, and the ‘survival rate’. With the advent of new classes of GEBT-drugs, the concept of ‘treat to target’ has been formed, in accordance with which the importance of achieving clear or almost clear skin as a goal of psoriasis therapy has been noted, since studies have shown that achieving clear or almost clear skin (PASI 90, 100) correlates with higher indicators of health-related quality of life. The concept is reduced to the long-term prescription of highly effective and safe therapies (methods) with a high level of evidence in medicine (A, B). The evolution of GIBT has led to the emergence of a new class of anti-IL-23 drugs. The article presents data from clinical studies on the effcacy and safety of the use of the interleukin-23 blocker guselcumab. Own clinical cases are presented with a discussion of the choice made in favor of guselcumab as the frst genetically engineered drug.Conclusions. Data from clinical trials on the high effcacy, ‘survival rate’ and safety of guselcumab in patients with psoriasis and psoriatic arthritis allows, including those with comorbid pathology, to consider it as a starting therapy using genetically engineered drugs. The data of our own results of observation allow us to conclude that guselkumab is highly effective in psoriasis of smooth skin, as well as in lesions of the scalp, anogenital area, with involvement of the nail plates in the process, which justifes its appointment as the frst GIBT drug.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

Cited by 9 publications

References 113 publications

Supportive local treatment of diseases of the distal colon of various inflammatory genesis in the outpatient department

Supportive local treatment of diseases of the distal colon of various inflammatory genesis in the outpatient department

Ankylosing spondylitis in combination with Crohn's disease: clinical case

Choice of frst drug of genetically engineered therapy: Benefts of guselcumab

Contact Info

Product

Resources

About